ANNEX 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Member States must ensure that all conditions or restrictions with regard to the safe and effective 
use of the medicinal product described below are implemented in their national territory: 
 
Prior to launch of the new indication of the product in the Member State, the national competent 
authority shall agree the content and format of the educational material with the Marketing 
Authorisation Holder 
 
The Marketing Authorisation Holder (MAH) should ensure that, at launch of the new indication, 
all Healthcare Professionals who are expected to use and/or prescribe INOmax as part of the 
treatment of peri- or post- operative pulmonary hypertension in adults and children  in 
conjunction to heart surgery are provided with an Educational pack.  
The educational pack should contain the following: 
 
Summary of Product Characteristics and Patient Information Leaflet for INOmax 
 
Educational material for Healthcare Professionals 
The educational material should be a pocket size guide that includes information on the following key 
elements: 
 
 
The risk of rebound effect and the precautions to take when discontinuing the treatment 
The risk of abrupt discontinuation of Inomax therapy in the event of critical failure of the 
delivery system and how to prevent it  
The monitoring of Methaemoglobin level  
The monitoring of NO2 formation  
The potential risk of bleeding and haemostasis disorders 
The potential risks if used in combination with other vasodilators which act on cGMP or cAMP 
 
 
 
 
2 
 
 
 
 
 
 
